Esophageal cancer trial mixes chemo, radiation, and immunotherapy

NCT ID NCT06401447

Ongoing Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding an immunotherapy drug (sintilimab) and immune-supporting agents to a medium-dose chemo-radiation regimen can improve outcomes for people with advanced esophageal cancer. About 50 participants will receive the combination, along with probiotics and thymosin alpha-1. The study focuses on how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paclitaxel, cisplatin, 5-FU, sintilimab, probiotics (Clostridium Butyricum), thymosin alpha-1
What this could lead to: If successful, this combination could improve how well chemoradiotherapy works for advanced esophageal cancer, potentially extending how long patients live without the cancer growing.
What could go wrong: This is a small, early-phase study with only 50 participants and no comparison group. The added drugs may increase side effects, and the benefits seen may not hold up in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.